Thermoresponsive hyaluronate-based nanogels for enhanced phenanthriplatin delivery in cisplatin-resistant ovarian cancer

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F70883521%3A28110%2F25%3A63596838" target="_blank" >RIV/70883521:28110/25:63596838 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00141724 RIV/00216208:11110/25:10500143 RIV/70883521:28610/25:63596838
Result on the web
<a href="https://pubs.acs.org/doi/10.1021/acs.biomac.5c00692" target="_blank" >https://pubs.acs.org/doi/10.1021/acs.biomac.5c00692</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1021/acs.biomac.5c00692" target="_blank" >10.1021/acs.biomac.5c00692</a>

Result language
angličtina
Original language name
Thermoresponsive hyaluronate-based nanogels for enhanced phenanthriplatin delivery in cisplatin-resistant ovarian cancer
Original language description
Stimuli-responsive hyaluronic acid carriers face limitations due to limited carboxyl groups, which are divided between drug conjugation and functional modifications. Thermoresponsive nanogels based on selectively oxidized hyaluronan (2,3-dicarboxy hyaluronate, DCH) grafted with poly(N-isopropyl acrylamide) (pNIPAM) were developed for phenanthriplatin (PhPt) delivery. Sequential oxidation after pNIPAM grafting introduced additional carboxylic groups, enabling a more efficient drug loading and controlled release. Compared to nonoxidized pNIPAM-modified HA, this approach achieved 3 times higher loading efficacy and significantly slower drug release. Upon PhPt loading, DCH-pNIPAM conjugates self-assembled into nanogels, with the drug binding mode (ionic vs covalent) influencing particle rearrangement and drug release behavior. Covalently bound PhPt showed reduced release compared to nonthermoresponsive controls. In vitro studies on ovarian cancer cell lines, including cisplatin-resistant variants, demonstrated up to an 18-fold increase in cytotoxicity versus free PhPt. These nanogels offer a promising strategy for enhancing drug efficacy, reducing off-target effects, and overcoming resistance in cancer therapy.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10404 - Polymer science

Project
<a href="/en/project/NW24-03-00331" target="_blank" >NW24-03-00331: Selectively modified betaglucans as immunoactivatory carriers of anticancer drugs for the treatment of colon cancer</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)